Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection

被引:0
|
作者
Vitikainen, Krista [1 ]
Kase, Merit [2 ]
Meriranta, Leo [2 ]
Molander, Pauliina [3 ,4 ]
af Bjorkesten, Clas-Goran [3 ,4 ]
Anttila, Veli-Jukka [4 ,5 ]
Arkkila, Perttu [3 ,4 ]
机构
[1] HUS Helsinki Univ Hosp, Haartmaninkatu 4,POB 340, Helsinki 00029, Finland
[2] HUS Helsinki Univ Hosp, Helsinki, Finland
[3] HUS Helsinki Univ, Abdominal Ctr, Gastroenterol, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
[5] Helsinki Univ Hosp, Dept Infect Dis, Helsinki, Finland
关键词
<italic>Clostridioides difficile</italic>; gastrointestinal infections; inflammatory bowel disease; HEALTH-CARE EPIDEMIOLOGY; HOSPITALIZED-PATIENTS; AMERICA IDSA; GUIDELINES; MANAGEMENT; IMPACT; RISK; DIAGNOSIS; COLECTOMY; COLITIS;
D O I
10.1177/17562848251318292
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Clostridioides difficile infection (CDI) is a clinical challenge associated with poor outcomes in patients with inflammatory bowel disease (IBD).Objectives: To identify clinical risk factors for CDI and its recurrence among patients with IBD.Design: Case-control cohort study of IBD patients with and without episodes of CDI.Methods: A case-control study of 279 IBD patients with CDI. Medical history and IBD-related symptoms 3 months preceding a toxin-positive CDI were recorded and compared with age- and sex-matched IBD patients without CDI. Outcomes of CDI in IBD patients were recorded 2-6 months after CDI.Results: Based on clinical symptoms and fecal calprotectin levels, IBD is active before CDI. Recently diagnosed IBD seemed to increase the risk for CDI. Corticosteroid usage frequently preceded CDI episodes. Advanced therapies were not associated with CDI. Antibiotic intake was not registered before CDI in 30% of the episodes. Recurrent CDI (rCDI) occurred in 30% (84/279) of IBD-CDI patients and 67% (90/135) of those episodes were registered within 90 days from the preceding episode. Most (79%) rCDI patients had ulcerative colitis (UC). CDI could complicate underlying IBD by increasing the need for escalation in IBD-related medical therapy and leading to hospitalization but it did not seem to increase the risk of colectomy.Conclusion: The major risk factors associated with CDI in IBD patients were IBD activity before infection, UC and colonic Crohn's disease, short duration of IBD, corticosteroid usage, and hospitalization. Patients with active IBD and a shorter disease duration may benefit from more frequent follow-ups in the early stages, as they appear to be at higher risk of developing CDI.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Application of Procalcitonin for the Rapid Diagnosis of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease
    Xie, Shuhua
    Chen, Peisong
    Wang, Dong
    Jiang, Xiaobing
    Wu, Zhongwen
    Liao, Kang
    Liu, Min
    Zhang, Shihong
    Chen, Yili
    DIAGNOSTICS, 2022, 12 (12)
  • [22] Clostridium difficile Infection in Patients with Inflammatory Bowel Disease
    Fu, Nancy
    Wong, Titus
    CURRENT INFECTIOUS DISEASE REPORTS, 2016, 18 (06)
  • [23] Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
    Albarrak, Abdulmajeed A.
    Romana, Bhupinder S.
    Uraz, Suleyman
    Yousef, Mohamad H.
    Juboori, Alhareth A.
    Tahan, Veysel
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2019, 19 (07) : 929 - 935
  • [24] Vancomycin in the treatment of inflammatory bowel disease: there is a role beyond Clostridioides difficile infection
    Calderon, Paula
    Damas, Oriana M.
    Nunez, Paulina
    Quera, Rodrigo
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (09) : 500 - 501
  • [25] Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
    Lam, Angela Y.
    Gutin, Liat S.
    Nguyen, Yume
    Velayos, Fernando S.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (11) : 3111 - 3115
  • [26] Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection
    Yu, Si
    Ge, Xiaomeng
    Xu, Hui
    Tan, Bei
    Tian, Bowen
    Shi, Yujie
    Dai, Yimin
    Li, Yue
    Hu, Songnian
    Qian, Jiaming
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [27] Clostridium difficile in inflammatory bowel disease
    Alhobayb, Tamara
    Ciorba, Matthew A.
    CURRENT OPINION IN GASTROENTEROLOGY, 2023, 39 (04) : 257 - 262
  • [28] Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals
    Stallmach, Andreas
    Anttila, Veli-Jukka
    Hell, Markus
    Gwynn, Simon
    Merino-Amador, Paloma
    Petrosillo, Nicola
    Racil, Zdenek
    Warren, Tim
    Wenisch, Christoph
    Wilcox, Mark
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (07): : 731 - 737
  • [29] Outcomes of clostridioides difficile infection on inflammatory bowel disease patients undergoing colonic resection: A propensity score weighted NSQIP analysis
    Connelly, Tara M.
    Holubar, Stefan D.
    Clancy, Cillian
    Cheong, Ju Yong
    Jia, Xue
    Bhama, Anuradha R.
    Lightner, Amy L.
    Kessler, Hermann
    Valente, Michael
    Liska, David
    AMERICAN JOURNAL OF SURGERY, 2023, 225 (03) : 553 - 557
  • [30] Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Khoruts, Alexander
    Fischer, Monika
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (02) : 313 - 319